accessdata.fda.gov
Lurasidone hydrochloride (HCl; Latuda; Sunovion Pharmaceuticals), an oral atypical antipsychotic, was approved by the US Food and Drug Administration (FDA) for 2 new indications - as monotherapy, and as adjunctive therapy with lithium or with valproate for the treatment of adult patients with major depressive episodes associated with bipolar I disorder (bipolar depression).